Glyscend Therapeutics
PrivateLast Round
Series A
Jun 11, 2020
Total Funding Raised
$22.7M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Glyscend Therapeutics is a biopharmaceutical company developing oral, first-in-class gut-targeted polymer therapies for the treatment of type 2 diabetes and obesity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glyscend Therapeutics Comparables
Compare Glyscend Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AltrixBio Inc. | 91% | |
| Syntis Bio, Inc. | 86% | |
| Aphaia Pharma | 81% |
Glyscend Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 11, 2020 | ||||
| Grant | Sep 15, 2017 | ||||
| Grant | May 25, 2017 | ||||
| Grant | Nov 14, 2016 | ||||
| Grant | Jul 1, 2015 |
Glyscend Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thiel Foundation | Seed, Series A |
| TEDCO | Convertible Debt |
| Santé Ventures | Series A |
| Breakout Ventures | Seed, Series A |
| Santé Ventures | Series A |
| Johnson & Johnson Innovation - JJDC, Inc. | Grant |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 2168% MoM, reaching 1.5K.
- Jun 11, 2020
$21M round led by Brandon Capital and Santé Ventures.
Glyscend Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Glyscend Therapeutics's valuation, stock price, and market status.
Is Glyscend Therapeutics a public or private company?
Glyscend Therapeutics is a private company.
What is the current stock price of Glyscend Therapeutics?
Glyscend Therapeutics is a private company, so its shares have no public market price. Caplight tracks Glyscend Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Glyscend Therapeutics worth (valuation)?
Valuation information for Glyscend Therapeutics is not publicly available.
Can I buy Glyscend Therapeutics stock?
Glyscend Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Glyscend Therapeutics's last funding round?
Glyscend Therapeutics's most recent funding round was Series A on June 11, 2020.
Who are the main investors in Glyscend Therapeutics?
Key investors in Glyscend Therapeutics include Santé Ventures, Santé Ventures, Brandon Capital.
Will Glyscend Therapeutics IPO soon?
No public IPO plans have been announced for Glyscend Therapeutics.
How can I track Glyscend Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Glyscend Therapeutics's shares on secondary markets.